Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Technology appraisal guidance
Reference number: TA540
Published:
Last updated:
This appraisal has been rescheduled to allow the company to obtain further data to inform their submission. The first committee will now take place on 5 December 2017.